Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: A method for executing a plurality of processing requests performed by a physical computing system that is programmed to execute the processing requests for clients includes, with the physical computing system, assigning an identification number to a new processing request; with the physical computing system, placing the new processing request into a process eligible group if the identification number of the new processing request meets a criterion; and with the physical computing system, placing the processing request into a queued group if the identification number of the processing request does not meet the criterion.

Abstract: A system of non-uniformity correction (NUC) for a pixel in an imaging array includes: a storage module for storing (a) a first gain coefficient for correcting a gain error of the pixel and (b) multiple damping factors, including a first damping factor, for adjusting the first gain coefficient, in response to multiple respective light levels that the pixel senses during operation. Also included is a NUC corrector module for receiving a first intensity value from the pixel in response to a first light level. The NUC corrector module extracts the first gain coefficient and a first damping factor from the storage module, and then corrects the first intensity value of the pixel using the (a) first gain coefficient and (b) first damping factor.

Abstract: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: A method of fusing two images includes adjusting contrast of (a) a visual image and (b) a thermal image. Also included is modifying the adjusted contrast of the thermal image to form output brightness levels, by using a transformation curve, and then displaying both (a) the brightness levels of the thermal image and (b) the adjusted contrast of the visual image. Modifying the adjusted contrast of the thermal image includes using a V-curve as the transformation curve, in which the V-curve includes similar maximum output brightness levels at the coldest and hottest relative temperatures, respectively. The V-curve also includes a minimum output brightness level at a midpoint between the coldest and hottest relative temperatures. Furthermore, the method assigns different hues to the intensity values of the thermal image, ranging from coldest to hottest relative temperatures.

Abstract: A method of enhancing an image includes: dividing the input image into multiple tiles; and constructing a respective histogram for each respective multiple tile. The method further includes: dividing each respective histogram into multiple portions, in which each portion represents a count of pixels spanning across pixel intensity value bands. The method also includes: constructing a respective cumulative distribution function (CDF) for each of the multiple portions; and transforming each of the multiple portions using the respective CDF. Each histogram may be divided, as an example, into two portions.

Abstract: A method of enhancing an image. This includes the steps of: dividing the image into multiple tiles and constructing a histogram for each tile, wherein the histogram represents a distribution of pixel intensity values in each tile. In addition, the method applies a bias value to the histogram and a plateau value to the histogram. A cumulative histogram is constructed after applying the bias value and the plateau value to the histogram. The method transforms each pixel in the image, by weighing four cumulative histograms, respectively, in four adjacent and closest tiles to the pixel under consideration. The pixel under consideration is modified based on a weighted cumulative histogram.

Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract: A method for executing a plurality of processing requests performed by a physical computing system that is programmed to execute the processing requests for clients includes, with the physical computing system, assigning an identification number to a new processing request; with the physical computing system, placing the new processing request into a process eligible group if the identification number of the new processing request meets a criterion; and with the physical computing system, placing the processing request into a queued group if the identification number of the processing request does not meet the criterion.